PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
EBIT growth above 1.5x TRVN's 14.24%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
-121.69%
Negative operating income growth while TRVN is at 14.24%. Joel Greenblatt would press for urgent turnaround measures.
-139.60%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-131.82%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-131.82%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-31.70%
Negative OCF growth while TRVN is at 37.31%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-31.70%
Negative FCF growth while TRVN is at 37.31%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 3Y CAGR while TRVN stands at 1106.46%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
95.37%
10Y OCF/share CAGR above 1.5x TRVN's 49.15%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
75.95%
Positive OCF/share growth while TRVN is negative. John Neff might see a comparative advantage in operational cash viability.
7.00%
Positive 3Y OCF/share CAGR while TRVN is negative. John Neff might see a big short-term edge in operational efficiency.
81.58%
Net income/share CAGR 1.25-1.5x TRVN's 60.68%. Bruce Berkowitz might see more effective use of capital or consistently better margins over time.
47.75%
Positive 5Y CAGR while TRVN is negative. John Neff might view this as a strong mid-term relative advantage.
-122.09%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
-94.45%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
58.16%
Positive 5Y equity/share CAGR while TRVN is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
-73.50%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.73%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-21.56%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-8.90%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
60.05%
We increase R&D while TRVN cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
231.77%
SG&A growth well above TRVN's 10.57%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.